REG - Aptamer Group PLC - Notice of Results and Investor Presentation

AptamerAnnouncement

17/10/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241017:nRSQ5031Ia&default-theme=true

RNS Number : 5031I  Aptamer Group PLC  17 October 2024

17 October 2024

 

Aptamer Group plc

 

("Aptamer", the "Company" or the "Group")

 

Notice of Results and Investor Presentation

 

Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to
enable innovation in the life sciences industry, will announce its full year
results for the year ended 30 June 2024 on Tuesday, 22 October 2024.

 

The Company is pleased to announce that Dr Arron Tolley, Chief Executive
Officer and Andrew Rapson, Chief Financial Officer will provide a live
presentation relating to the full year results via Investor Meet Company on
Tuesday, 22 October 2024 at 2:00 pm GMT.

 

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via your Investor Meet Company dashboard or at any
time during the live presentation.

 

Investors can sign up to Investor Meet Company for free and add to meet
Aptamer Group plc via:

https://www.investormeetcompany.com/aptamer-group-plc/register-investor
(https://www.investormeetcompany.com/aptamer-group-plc/register-investor)

 

Investors who already follow Aptamer Group plc on the Investor Meet Company
platform will automatically be invited.

 

- Ends -

 

For further information, please contact:

 

 Aptamer Group plc                                               +44 (0) 1904 217 404 

 Arron Tolley 
 SPARK Advisory Partners Limited - Nominated Adviser             +44 (0) 20 3368 3550 

 Andrew Emmott / Adam Dawes 
 Turner Pope Investments (TPI) Limited - Broker                  +44 (0) 20 3657 0050 

 James Pope / Andrew Thacker 
 Northstar Communications Limited - Investor Relations           +44 (0) 113 730 3896

 Sarah Hollins

 

About Aptamer Group plc

 

Aptamer Group develops custom affinity binders through its proprietary
Optimer(®) platform to enable new approaches in therapeutics, diagnostics,
and research applications. The Company strives to deliver transformational
solutions that meet the needs of life science researchers and developers.
Optimer binders are oligonucleotide affinity ligands that can function as an
antibody alternative. The global affinity ligand market is currently worth
over $170 billion.

 

Aptamer has successfully delivered projects for a range of global pharma
companies, diagnostic development companies, and research institutes, covering
multiple application areas with the objective of establishing royalty-bearing
licenses.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORMFBRTMTJBBJI